Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Nuvalent is a clinical-stage precision oncology company developing brain-penetrant kinase inhibitors targeting ROS1-positive and ALK-positive non-small cell lung cancer (NSCLC) and other solid tumors. The company's lead asset, zidesamtinib (NVL-520), is in Phase 2 trials for ROS1+ NSCLC with differentiated CNS penetration, while NVL-655 targets ALK+ NSCLC including resistant mutations. With $1.1B+ cash (estimated based on 10.73 current ratio and negative burn rate) and no revenue, the stock trades on clinical trial readouts, regulatory milestones, and partnership potential.
Nuvalent operates a research-driven model focused on developing best-in-class tyrosine kinase inhibitors (TKIs) with superior brain penetration for oncogene-driven cancers. The company's proprietary chemistry platform designs molecules optimized for CNS activity, targeting the 30-40% of ROS1+/ALK+ NSCLC patients who develop brain metastases. Revenue generation depends on successful Phase 2/3 trials, FDA/EMA approvals (estimated 2027-2028 timeline for potential first approval), and commercialization either independently or through partnerships. Pricing power in rare oncology indications typically supports $150K-200K+ annual treatment costs. The company competes against Pfizer's lorlatinib (ALK) and Roche's entrectinib (ROS1), differentiated by mutation coverage and CNS efficacy.
Clinical trial data readouts for zidesamtinib (NVL-520) in ROS1+ NSCLC - objective response rates (ORR), duration of response (DOR), and intracranial activity
NVL-655 Phase 1/2 data in ALK+ NSCLC, particularly activity against lorlatinib-resistant mutations and CNS metastases
FDA regulatory interactions - IND clearances for new programs, breakthrough therapy designations, or accelerated approval pathways
Strategic partnerships or licensing deals with large pharma for ex-US rights or combination therapy development
Competitive developments from Pfizer, Roche, Takeda, or emerging TKI developers affecting market positioning
Binary clinical trial risk - Phase 2/3 failures would eliminate near-term value as ROS1+ NSCLC affects only ~2,000-3,000 US patients annually (1-2% of NSCLC), requiring high efficacy for commercial viability
Regulatory pathway uncertainty for accelerated approval in rare oncology indications with evolving FDA standards for single-arm trials and surrogate endpoints
Reimbursement pressure as payers scrutinize oncology drug pricing, particularly for incremental improvements over existing TKIs like crizotinib or entrectinib
Pfizer's lorlatinib dominance in ALK+ market with established efficacy and CNS penetration creates high bar for NVL-655 differentiation
Emerging next-generation TKIs from Turning Point Therapeutics (acquired by BMS), Relay Therapeutics, and others targeting same mutations with alternative mechanisms
Combination therapy strategies from competitors pairing TKIs with immunotherapy or chemotherapy could obsolete monotherapy approaches
Cash runway risk - estimated 5-6 quarters of funding at current burn rate requires equity raises in 2026-2027, creating dilution risk and dependence on favorable market conditions
Negative ROE (-39.5%) and ROA (-38.9%) reflect ongoing losses typical of clinical stage, but extended timelines increase cumulative dilution to existing shareholders
No debt provides flexibility but also means no tax shield benefits and full reliance on equity markets for capital
low - Clinical trial timelines and regulatory processes are largely insulated from GDP fluctuations. However, severe recessions can impact: (1) capital markets access for future financing rounds, (2) pharma M&A appetite and partnership valuations, and (3) healthcare system capacity for trial site operations. Oncology drug demand is non-discretionary and recession-resistant post-approval.
Rising rates negatively impact valuation through higher discount rates applied to distant cash flows (first revenues likely 2028+). Clinical-stage biotech with 5-7 year commercialization timelines are particularly sensitive to the risk-free rate used in DCF models. Higher rates also increase opportunity cost versus bonds for growth investors and can compress biotech sector multiples. Minimal direct business impact as the company carries no debt (0.00 D/E ratio), but future financing costs and dilution risk increase if equity markets weaken.
Minimal direct credit exposure. The company operates with zero debt and strong liquidity (10.73 current ratio). Credit conditions affect: (1) venture debt availability as non-dilutive financing option, (2) pharmaceutical partner financial health for potential deals, and (3) institutional investor risk appetite for pre-revenue biotech. Tightening credit can reduce crossover fund participation and compress valuations.
growth - Attracts specialized biotech investors, healthcare-focused hedge funds, and venture capital crossover funds seeking high-risk, high-reward clinical-stage opportunities. The 29.1% one-year return and 36.3% six-month return reflect momentum from positive clinical updates. Institutional ownership likely concentrated among funds with oncology expertise (Fidelity, T. Rowe Price biotech teams). Not suitable for value or income investors given zero revenue, negative margins, and no dividend. Requires tolerance for binary event risk and 3-5 year investment horizons.
high - Clinical-stage biotech exhibits extreme volatility around data readouts, with 20-50% single-day moves common on trial results. Beta likely 1.5-2.0x versus broader market. The -1.9% three-month return versus +36.3% six-month shows event-driven volatility. Small-cap biotech ($7.4B market cap) with low float liquidity amplifies price swings. Volatility increases approaching key catalysts (Phase 2 data expected 2026-2027).
